These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11434275)

  • 1. [Interferon in multiple sclerosis. The earlier, the better?].
    MMW Fortschr Med; 2001 May; 143 Suppl 2():94. PubMed ID: 11434275
    [No Abstract]   [Full Text] [Related]  

  • 2. Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-beta.
    McDonald WI; Miller DH; Thompson AJ
    Ann Neurol; 1994 Jul; 36(1):14-8. PubMed ID: 8024255
    [No Abstract]   [Full Text] [Related]  

  • 3. Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
    Benatar M
    Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424021
    [No Abstract]   [Full Text] [Related]  

  • 4. [Long-term interferon therapy. Effectiveness in multiple sclerosis continues].
    MMW Fortschr Med; 2002 May; Suppl 2():84. PubMed ID: 12070862
    [No Abstract]   [Full Text] [Related]  

  • 5. [Beta interferon and multiple sclerosis].
    Kinnunen E
    Duodecim; 1996; 112(24):2368-73. PubMed ID: 10605237
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of interferon-beta in the treatment of multiple sclerosis.
    Derwenskus J; Lublin FD
    Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
    [No Abstract]   [Full Text] [Related]  

  • 7. Interferon-beta1a treatment for multiple sclerosis.
    Sandberg-Wollheim M
    Expert Rev Neurother; 2005 Jan; 5(1):25-34. PubMed ID: 15853471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS.
    Durelli L
    J Neurol; 2003 Dec; 250 Suppl 4():IV9-IV14. PubMed ID: 14712396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interferon-beta treatment of progressive disseminated sclerosis. Is it possibly without effect?].
    Foldspang A
    Ugeskr Laeger; 1999 Aug; 161(31):4418-21. PubMed ID: 10487112
    [No Abstract]   [Full Text] [Related]  

  • 11. [A short history of beta-interferon therapy of multiple sclerosis].
    Stock G; Horowski R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New approaches in research of therapy of multiple sclerosis].
    Hemmer B; Cepok S; Nessler S; Sommer N
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():23-8. PubMed ID: 11603112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta interferons for multiple sclerosis.
    Med Lett Drugs Ther; 2002 Oct; 44(1141):88-9. PubMed ID: 12381969
    [No Abstract]   [Full Text] [Related]  

  • 14. [Interferon beta-1a].
    Taéron C
    Rev Infirm; 2004 May; (101):39-40. PubMed ID: 15984751
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
    Vartanian T; Sölberg Sørensen P; Rice G
    J Neurol; 2004 Jun; 251 Suppl 2():II25-30. PubMed ID: 15264109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-beta treatment in patients with childhood-onset multiple sclerosis.
    Mikaeloff Y; Moreau T; Debouverie M; Pelletier J; Lebrun C; Gout O; Pedespan JM; Van Hulle C; Vermersch P; Ponsot G
    J Pediatr; 2001 Sep; 139(3):443-6. PubMed ID: 11562627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-beta therapy for MS: the dilemma of having choices.
    Khan O
    J Neurol Sci; 2004 Jul; 222(1-2):1. PubMed ID: 15240187
    [No Abstract]   [Full Text] [Related]  

  • 18. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
    Giacomini PS; Arnold DL; Bar-Or A; Antel JP
    Arch Neurol; 2009 Jan; 66(1):19-20. PubMed ID: 19139295
    [No Abstract]   [Full Text] [Related]  

  • 19. Advancing treatment with interferon beta-1b (Betaferon/Betaseron) in the next decade--thinking beyond the standard dose.
    Cook SD
    J Neurol; 2003 Dec; 250 Suppl 4():IV15-20. PubMed ID: 14712397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of interferon beta in relapsing-remitting multiple sclerosis.
    Etheridge LJ; Beverley DW; Ferrie C; McManus E
    Arch Dis Child; 2004 Aug; 89(8):789-91. PubMed ID: 15269086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.